With recent changes in United Network for Organ Sharing policy, patients in the United States with hepatocellular carcinoma (HCC) are likely to spend more time on the liver transplantation (LT) waiting list. The increasing wait time will allow for an opportunity to assess tumor biology prior to LT. Modified Response Evaluation Criteria in Solid Tumors (mRECIST) paradigm provides such a framework for this assessment, and yet little is understood of its utility as it would apply for patients listed for LT in the United States. Through a collaboration between the University of California, San Francisco, and the Mayo Clinic, Jacksonville, Florida, the experience of 772 patients listed for LT were retrospectively reviewed to study the impact of immediate mRECIST classification following locoregional therapy (LRT) on pre-and post-LT outcomes. Patients who had progression of disease (PD; n = 72), failed to respond to LRT (n = 89) at any time point, or did not achieve radiologic complete response (CR; n = 224) were all at significant risk for wait-list dropout (odds ratio [OR] = 12.11, 4.81, and 2.48; respectively). CR identified a cohort of patients who were at a reduced risk for wait-list dropout. However, 24.9% eventually required further intervention while waiting for transplant, and as many as 82.4% were found to have residual HCC on explant pathology. Failure to respond to LRT was associated with increased risk for recurrence (OR = 3.00) more so than PD (OR = 1.36), suggesting that despite PD, patients who eventually can respond to LRT may represent favorable candidates for LT. In conclusion, for patients awaiting LT, the mRECIST assessment provides critical guidance for patient management. Although PD portends a poor prognosis, our findings suggest that further aggressive LRT should be pursued because a response to LRT may yield acceptable results for patients awaiting LT as well as after LT.
Original article | 229 correlated with post-LT survival. Also, the authors demonstrated that LRT benefited post-LT outcomes only in the setting of complete pathologic response. (8) Alternatively, some groups have questioned whether patients who achieve complete response (CR) should be prioritized for LT at all. (9) And as a result, much debate exists regarding prioritization for patients with HCC and their access to LT. (10) (11) (12) In 2015, United Network for Organ Sharing (UNOS) implemented a modification to the prior allocation policy for granting automatic MELD exception points to candidates with HCC, requiring a candidate to be listed with their calculated MELD score for 6 months prior to receiving an automatic MELD exception score. (13) The intent of this policy change was to increase equity in access to transplants for all patients on the waiting list and to improve pretransplant and posttransplant outcomes for patients with HCC. (11) By delaying expedited access to LT for patients with HCC, transplant centers could observe tumor biology to potentially exclude patients with aggressive tumors who may have poor post-LT outcomes. As a result, wait times for patients with HCC across all UNOS regions would likely increase, and more transplant centers would be reliant on the use of LRT to mitigate the inherent risk of tumor progression and wait-list dropout. With extended wait time and LRT to test the tumor biology, this new policy had created an opportunity to approach HCC in a more calibrated way. In 2008, a panel of experts convened by the American Association for the Study of Liver Diseases developed a set of guidelines to standardize the measurement of treatment response by defining viable tumor tissue as arterial phase uptake of contrast in the setting of contrast-enhanced cross-sectional imaging. (14) The modified Response Evaluation Criteria in Solid Tumors (mRECIST) became adopted as a standardized way to define the biological behavior of HCC radiologically.
To that end, the use of mRECIST as a surrogate marker for tumor biology has been proposed. However, no such study has demonstrated this definitively in the context of LT practice in the United States as limited by UNOS policy and transplant center behavior. Herein, we describe the combined experience of 2 large transplant centers with a total of 772 patients listed for LT, and we retrospectively review pre-LT and post-LT outcomes for patients along the spectrum of mRECIST classification.
Patients and Methods

stUDY Design anD patient pOpUlatiOn
Through a collaboration and a priori institutional review board approval at each center with the University of California, San Francisco (UCSF), California, and Mayo Clinic, Jacksonville, Florida, data were collected from all patients aged 18 years and older with HCC based on preoperative imaging listed for LT from January 2004 until March 2013. The variables collected included demographic data (age, sex, and race/ethnicity), tumor-related factors (size and number at time of HCC diagnosis, alpha-fetoprotein [AFP] at the time of listing and transplant, and number of LRTs received), and liver-related factors (etiology of liver disease and MELD score). Total tumor volume (TTV) was determined as has previously been described. (15) The decisions regarding management of patients with HCC awaiting LT were made at each center's multidisciplinary Liver Tumor Board attended by transplant hepatologists, transplant surgeons, oncologists, interventional radiologists, and radiologists with an expertise in diagnostic abdominal imaging.
Among patients who underwent LT, explant pathology was reviewed to determine histologic grade based on the modified Edmondson criteria (grade 1, well differentiated; grade 2, moderately differentiated; and grade 3, poorly differentiated), (16) tumor stage, and presence of vascular invasion. Explant tumor staging in this study was based on size and number of only the viable tumors, and results were correlated with UNOS staging. (13) 
evalUatiOn OF tUMOr respOnse
For assessment of treatment response, all patients were categorized according to the mRECIST criteria by comparing the pre-LRT lesions (number of lesions and size) to the first post-LRT radiological assessment, usually within the 3 months following LRT. (17) Subsequent LRTs were reassessed by mRE-CIST classification. CR was defined as the disappearance of the target lesion; partial response (PR) was defined as at least 30% decrease in size of the target lesion; progression of disease (PD) was defined as at least a 20% increase in size of the target lesion; and stable disease was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Classification for patients was treated dynamically because patients' mRECIST after the first LRT may be different than subsequent LRTs. The purpose of this study was to provide guidance for patient management on the waiting list, and as the tumor biology of the patient provides changing information in response to repeated LRTs, the mRECIST classification was adjusted. Progression on the waiting list was classified for any patient who following mRECIST demonstrated PD, but this should not imply that the patient did not subsequently respond to LRT on a later treatment. Failure to respond to LRT was noted if the patient did not ever achieve either PR or CR following any LRT while awaiting LT. The CR distinction was noted when a patient achieved radiologic CR following any LRT while on the waiting list. Despite achieving CR, patients could go on to develop recurrence of the same tumor or develop a new lesion, which was then treated again with LRT and reclassified according to mRECIST.
OUtcOMes
The primary outcome studied was post-LT HCC recurrence, which was obtained from each individual center's LT database. Additional outcomes measured included post-LT survival as well as dropout from the transplant waiting list for any of the following reasons: death without LT, HCC tumor progression beyond T2 criteria, being too sick or medically unsuitable to undergo LT, noncompliance, patient decision not to undergo LT, or being lost to follow-up. Time to dropout or LT was measured from the date of HCC diagnosis to wait-list removal or LT, respectively.
statistical analYsis
Patient characteristics were summarized using mean, standard deviation (SD), median, and range for continuous variables and proportions for categorical variables. For comparison of nonnormally distributed variables, the natural log (ln) was used for comparison. Intention-to-treat survival and post-LT survival were evaluated using the Kaplan-Meier method. All causes of death or dropout were treated as events and incorporated in the survival models. Competing risk regression was performed using the methods described by Fine and Gray to determine the cumulative incidence of recurrence. (18) Univariate and multivariate odds ratios (ORs) for predictors of post-LT HCC recurrence were determined by logistic regression. This was performed for all variables known prior to transplant (eg, exclusion of explant data and AFP at transplant). Predictors of dropout and HCC recurrence with a univariate P value <0.01 were evaluated in the multivariate analysis with the final model selected by backward elimination (P value for removal >0.05). Statistical analyses were performed using Stata/IC, version 13.1 (Stata Corp., College Station, TX).
Results
In total, 772 patients met the inclusion criteria. On initial evaluation, 720 (93.2%) patients were within MC; 42 (5.4%) patients were within UCSF criteria and subsequently downstaged 3 (0.4%) patients were downstaged from beyond UCSF criteria; and 7 (0.9%) patients had pre-evaluation data that were unavailable. The mean number of lesions on imaging was 1.4 with a median of 1 and range of 1-6. The mean size of the largest lesion was 2.8 cm with a median of 2.6 cm and a range of 1-9.7 cm. The mean TTV was 157.7 cm 3 with a median of 83.4 and a range of 0-3823.3 cm 3 . Mean Alphafetoprotein (AFP) at listing was 272 ng/mL with a median of 14 ng/mL and a range of 1-29,581 ng/mL. In total, 314 (40.7%) patients received 1 LRT, 217 (28.1%) patients received 2 LRT, 130 (16.8%) patients received 3 LRT, and 110 (14.4%) patients received ≥4 LRT. The most common LRT was transarterial chemoembolization (TACE), which 428 (55.4%) patients received. There were 202
Original article | 231 (26.2%) patients who received both TACE and radiofrequency ablation, 70 (9.1%) patients received radiofrequency ablation alone, 51 (6.6%) patients received both TACE and another intervention such as EtOH ablation, microwave ablation, cryoablation, stereotactic body radiation therapy (SBRT), or radioembolization with yttrium 90 (y90). A total of 13 (1.7%) patients received only 1 treatment of ablative therapy.
In total, 559 (72.4%) patients were successfully transplanted, whereas 213 (27.6%) were delisted prior to transplant. Of the 213 patients who were delisted, 92 were delisted due to tumor progression, of which 75 (81.5%) died within the follow-up period. Another 69 patients were delisted due to worsening of liver disease or were too sick, of which 51 (73.9%) died within the follow-up period. Also, 52 (24.4%) patients were delisted either due to transferring to another center, refusing transplant, or were lost to follow-up. Of the patients who underwent transplantation, 85 (15.2%) patients had CR to LRT and had no evidence of HCC on explant. There were 142 (25.4%) patients who had UNOS T1 lesions; 232 (41.5%) patients had UNOS T2 lesions; 38 (6.8%) patients had lesions beyond UNOS T2 but within UCSF criteria; and 56 (10.0%) patients had lesions beyond UCSF criteria. Of the patients for whom tumor grade was available (436 patients), 156 (35.8%) patients had well-differentiated lesions; 178 (40.8%) had moderately differentiated lesions; and 28 (6.4%) had poorly differentiated lesions. A total of 40 (7.1%) patients had microvascular invasion. 
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Mean follow-up after LT was 4.1 years (median, 4.1 years; range, 0-12 years). Recurrence was seen in 53 (9.5%) patients with a mean time to recurrence of 16.2 months (median, 10.8; range, 0.5-57 months). Mean time from LRT to mRECIST assessment was 109 days (median, 75 days; range, 5-913 days). Mean time from last mRECIST assessment to transplant was 213 days (median, 157 days; range, 0-1599 days).
prOgressiOn On tHe list
After assessing the tumor response after every LRT for patients on the waiting list, we found that 72 patients (of 700, 10.3%) met criteria for PD. Of these 72 patients, only 16 (22.2%) patients ultimately underwent transplant, whereas 543 (77.6%) of the 700 patients without PD were successfully transplanted. There were no significant demographic differences between the patients who had PD and those who did not (Table 1 ). There was a statistically significant difference in the lnAFP at listing and at transplant, with the higher number found in the patients who had PD. Although the number of patients who made it to transplant was small (only 16), those who underwent transplantation tended to have higher-grade tumors (moderately differentiated or greater; 75.0% versus 35.7%; P < 0.01) and were more likely to have vascular invasion (25.0% versus 6.6%; P = 0.01; Original article | 233 Table 2 ). Intention-to-treat survival for patients who had PD versus those who did not was statistically worse (log-rank P < 0.01; Fig. 1A ). This is largely due to the fact that the majority of patients who had PD were delisted. Patients with PD who underwent transplantation also had a statistically significant worse posttransplant survival than those who did not have progression ( Fig. 2A) . The 1-, 3-, and 5-year survival rates were 80.0% versus 93.3%, 54.6% versus 83.1%, and 28.6% versus 71.0%, respectively (log-rank P = 0.03). However, cumulative incidence of posttransplant recurrence adjusted for competing risk was not statistically significantly worse for those with PD (P = 0.57).
respOnse tO lrt
While on the waiting list, 89 (11.5%) patients did not ever have a response to LRT (as defined by either PR or CR). Of these patients, only 36 (40.4%) made it to transplant, while 523 of the 683 (76.6%) patients who did respond to LRT were successfully transplanted. Intention-to-treat survival was statistically worse for patients who did not respond to LRT (Fig. 1B) . No significant demographic differences were noted between patients who did not have any response to LRT versus those who did (Table 3) . Those who did not respond to LRT, however, tended to have larger tumors (mean 3.1 versus 2.8 cm; P = 0.04), higher lnTTV at presentation (mean 5.3 versus 4.9 cm 3 ; Original article | 235 P = 0.01), and higher lnAFP at listing (mean 3.6 versus 3.0; P = 0.01). On explant, the patients who never responded to LRT were less likely to have a complete pathologic response (2.8% versus 16.1%; P = 0.03), and they were more likely to have vascular invasion (22.2% versus 6.1%; P < 0.001). Posttransplant survival was slightly worse for patients who did not have a response to LRT at 1, 3, and 5 years (88.4% versus 93.6%, 74.2% versus 85.5%, and 74.2% versus 79.8%), but this was not statistically significant (P = 0.24; Fig. 2B ). Cumulative incidence of posttransplant recurrence adjusted for competing risk was statistically significantly worse for patients who did not respond to LRT (P < 0.01; Fig. 3B ).
cOMplete respOnse
Of the 772 patients, 546 (70.7%) demonstrated radiologic CR of their treated lesion(s) following at least 1 LRT while on the waiting list. CR was achieved at some point on the waiting list. However, they may have later developed progression or developed a new lesion necessitating a subsequent LRT or may show a viable lesion on explant pathology. Of these 546 patients who achieved CR, 192 (35.2%) required a subsequent treatment while on the waiting list. Intention-to-treat demonstrated improved survival for patients listed who achieved CR (Fig. 1C) . No significant demographic differences were noted between patients who did not have CR versus those who did (Table 4) . Patients who NOTE: Data are given as mean ± SD (median, range) and n (%).
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did not have CR tended to have a higher MELD score (mean 12.3 versus 11.2; P < 0.01). Those patients who did not achieve CR also tended to have more tumors (mean 1.6 versus 1.4; P < 0.01) and to have a higher lnAFP at listing (mean 3.5 versus 2.9; P < 0.01). There were 426 patients (78% of the patients with CR) who were successfully transplanted. Of the remaining 120 patients, 34 (28.3%) patients were delisted due to progression of HCC beyond UNOS T2 staging and 44 (36.7%) patients were delisted due to liver disease. Following transplant, of those patients who had CR, only 75 (17.6%) had no evidence of tumor on explant and 351 (82.4%) still had residual viable tumor. Recurrence was seen in 30 (7.0%) patients with CR versus 17.3% in patients without CR (P < 0.001).
It should be noted that if a patient achieved CR on pathology, no recurrence was found after transplant. Posttransplant survival between no CR versus CR was not different at 1, 3, and 5 years (93.0% versus 92.9%, 82.2% versus 82.4%, and 72.9% versus 69.1%, respectively; log-rank P = 0.92; Fig. 2C ). Cumulative incidence of posttransplant recurrence adjusted for competing risk was statistically worse for patients who did not achieve CR versus CR (P = 0.001; Fig. 3C ).
risK OF DrOpOUt
To assess the risk of dropout, univariate analysis was performed for all pretransplant variables; lnAFP at listing, no response to LRT, PD, lnTTV at presentation, Original article | 237
and number of LRT all had statistically significant increased odds of dropout (Table 5 ). Multivariate analysis was performed and demonstrated that no response to LRT (OR = 2.26; P < 0.01), PD (OR = 8.24; P < 0.001), lnTTV (OR = 1.38; P < 0.01), and increasing number of LRT (OR = 1.29; P < 0.01) were all independently associated with increased risk for dropout.
risK OF recUrrence
The following known pretransplant variables were then modeled with univariate analysis to determine their impact on risk of recurrence: MC at time of diagnosis, AFP at initial diagnosis, lnTTV at initial diagnosis, number of LRT, progression on the list, and response to LRT (Table 5 ). PD and pretransplant MC status were not statistically significant risk factors for recurrence. Multivariate analysis was performed demonstrating that increasing lnAFP at listing (OR = 1.22; P = 0.01), no response to LRT (OR = 3.13; P = 0.02), increasing lnTTV (OR = 1.38; P = 0.04), and increasing number of LRTs (OR = 1.43; P = 0.01) were all statistically significant risk factors for recurrence, with no response to LRT providing the greatest OR for recurrence.
Discussion
The role of the mRECIST criteria in understanding HCC tumor biology for patients on the waiting list has yet to be fully elucidated. (19) In our review of 772 HCC patients listed for transplant, initial response to LRT as classified by mRECIST provided significant insight into the HCC tumor biology both on the waiting list as well as after transplant. Patients who do not have PD have 8.2 times the odds of being transplanted over those who do experience PD. On the other hand, patients who respond to LRT have 2.3 times the odds of being transplanted over those who do not ever respond to LRT while on the waiting list. As would be expected, the greatest survival for patients on the waiting list is determined by undergoing transplant. The intention-to-treat survival curves reflect better survival for all patients without PD-patients with either PR or CR-primarily because a higher percentage of them were successfully transplanted. The ability of mRECIST to predict posttransplant survival is less clear. Although there was a statistically significant worse survival for those patients with PD, when patients failed to respond to LRT at any time on the waiting list, they did not have statistically significant worse posttransplant survival. Certainly, there was diminished survival at 1, 3, and 5 years for patients who did not respond versus those who did (87.9% versus 93.3%, 69.2% versus 83.2%, and 55.6% versus 71.0%, respectively). However, this did not reach statistical significance. When comparing the results for patients who showed radiographic CR versus not, the posttransplant survival was not clearly different. These findings highlight the challenge of using posttransplant survival as an endpoint for pre-LT prediction models.
For recurrence, however, the use of mRECIST to identify patients at risk for post-LT recurrence is fairly clear. When modeling for the competing risk of death, recurrence is higher for patients who do not have any response to LRT while on the waiting list. Interestingly, PD was not a statistically significant risk factor for recurrence, either because the numbers were too small for accurate interpretation or due to the higher mortality in the first 3 years and patients did not live long enough for recurrence to be found. Despite that, our competing risks analysis did not demonstrate a higher cumulative incidence for recurrence. Of those patients with PD who made it to transplant, 56.2% never had a response to LRT, whereas 7 (43.8%) eventually did. Of the 7 patients who eventually did have a response to LRT, none of them had recurrence after transplant. For those NOTE: Using a retention criterion of P value < 0.1, a multivariate analysis was performed demonstrating that increasing lnAFP at presentation, no response to LRT, and increasing number of LRT were all statistically significant risk factors for recurrence, with no response to LRT providing the greatest OR for recurrence. Original article | 239 patients who did not respond to LRT and had PD, 2/9 or 22.2% had recurrence. Therefore, experiencing PD after LRT alone did not correlate with their recurrence but rather with their failure to respond to LRT. This implies the importance of aggressively seeking treatment for these lesions with the goal of eventually achieving some form of local control prior to transplant. From this experience, we realized that mRECIST PD, if left alone, is a significant risk factor for failure to reach transplant, poor survival, and even posttransplant survival. More importantly, if patients could achieve a response to LRT, they would experience a reduced risk of waitlist dropout and post-LT recurrence. We would also be able to identify patients with more favorable tumor biology -lesions with lower tumor grade and no vascular invasion. The role of mRECIST has been studied multiple different ways. Three groups have chosen the first mRECIST assessment following the first LRT at listing. (9, (20) (21) (22) We found this to be problematic because most studies have demonstrated that LRT is rarely curative and most patients developed some degree of progression as is evidenced by the high number of patients in our study who had greater than 1 LRT. This number is only likely to increase as waiting times extend for patients with HCC. We chose instead to follow patients on the waiting list and included each mRECIST assessment after each LRT. Another approach by other groups is to study either the first and last mRECIST assessments or just the last mRECIST assessments before transplant. (20, 23, 24) The difficulty with these studies is that the last mRECIST assessment before transplant will never be known a priori. Many of these studies corroborated our findings that progressive disease was associated with an increased risk for worse post-LT survival and also recurrence. However, in the setting of imaging just prior to LT, this provided more evidence that further LRT may have been beneficial prior to LT.
These data show that in the current US system for granting access to LT for patients with HCC within MC, mRECIST classifications may not be as effective at distinguishing post-LT mortality, but we certainly found that mRECIST response to LRT was significantly predictive for recurrence. When looking at recurrence specifically, we found that nonresponse to LRT had the most significant impact on the OR for recurrence risk, both in univariate and multivariate analyses.
Regarding CR, there has been growing evidence that prioritization for these patients may be unnecessary. Several groups have demonstrated that the least survival benefit was achieved in patients who had minimal liver disease and CR. (9, 25, 26) Their conclusions were supported by other work which showed that patients with favorable tumor size, CR after first LRT, and favorable AFP had a 1-and 2-year dropout percentage of 1.3% and 1.6%, respectively. (27) Long term, however, we observed in our cohort an overall 14.3% dropout with 6.4% due to HCC progression and 8.3% dropout due to liver disease among patients who achieved CR. These data lend support to the notion that allocation for these patients need to consider response to LRT (a proxy for tumor biology) to allow for more evidence-based prioritization for LT. Another important observation here is that despite an initial CR achieved for these patients, 24% did require further LRT while waiting for LT and after transplant more than 80% still had some residual HCC found on explant pathology. This finding suggests that despite an initial CR, over time while waiting on the list, patients are likely to still have some residual HCC, which with growth becomes apparent on pathology. In a recent study, Gordic et al. retrospectively reviewed the last magnetic resonance imaging (MRI) performed prior to LT and found that this image could fairly accurately predict pathologic CR. (28) These data collectively provide hope for a prospective trial that would compare an incremental approach to LT prioritization for patients who achieve CR, whereby patients who achieve CR may receive more modest prioritization for LT allocation and that response to LRT becomes the most important factor for MELD exception points. Necessary for such a trial would be close surveillance with MRI formatted to capture the sensitivity that Gordic et al. have described. (28) Our study has some limitations inherent to being a retrospective multicenter study. The heterogeneity and timing of the LRT treatments and LT between the participating centers could introduce confounding elements into our analysis. Despite this, recurrence rates and posttransplant survival were not statistically significantly different in either center. Because of the inherent regional differences between the 2 centers, wait time and dropout rates were significantly different. However, disease management was very much the same. Unique to this investigation is the opportunity to combine 2 large experiences from 2 different regions of the United States to examine in a uniform way the response to LRT and its impact on pretransplant and posttransplant outcomes as relevant for patients who have been accepted and listed for LT.
The intention of this analysis was to draw conclusions from mRECIST classifications for patients who are awaiting LT in the United States. The mRECIST assessment was dynamic for any given patient, and the patients, rather than individual tumors, were categorized. This approach was adopted because current policy focuses on patients with liver disease as the tumorigenic field defect, which generates the HCC biology.
In summary, we demonstrate that mRECIST correlates with outcomes for patients listed for LT in the United States. PD correlates with high dropout risk and poor posttransplant survival. Because of this finding as well as evidence that patients who fail to respond to LRT showed significantly worse wait-list survival as well as increased posttransplant recurrence risk, we strongly recommend caution in transplanting patients who fail to respond to LRT because this likely portends poor tumor biology. In patients with PD, we would recommend that continued aggressive treatment should be pursued to achieve a response. We have shown that patients with CR are at a reduced risk for dropout and have excellent posttransplant outcomes. Caution should be made toward delisting these patients because the survival benefit still appears to be had for transplant in this setting but not in the same urgent manner as other patients of equal MELD or more persistent HCC. Moving forward, as we consider using survival benefit and tumor biology to influence HCC allocation, we would need to investigate whether response to LRT could allow for a more calibrated approach to prioritization of patients with HCC.
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